Status:
TERMINATED
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
Lead Sponsor:
Molecular Insight Pharmaceuticals, Inc.
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately...
Eligibility Criteria
Inclusion
- Provide written informed consent and be willing to comply with all protocol requirements
- Men and women 18 years of age or older
- Female patients must meet 1 of the following criteria:
- not be of childbearing potential as documented by medical history (e.g., tubal ligation or hysterectomy), or be post menopausal with a minimum 1 year without menses
- Have a negative serum beta human chorionic gonadotropin (BHCG) pregnancy test within 48 hours prior to receiving the test article and agree to use a medically acceptable form of birth control, defined as abstinence or use of an intrauterine device (IUD), oral contraceptive, barrier and spermicide, or hormonal implant throughout the 28 day study period.
- Male patients of childbearing potential must agree to use at least one of the following medically acceptable forms of birth control throughout the 28 day study period; abstinence, barrier or other acceptable, effective contraceptive method.
- Historical diagnosis (surgical or histological) of primary melanoma with metastatic melanoma confirmed by histology and/or radiologically via MRI/CT.
- CT/MRI representing current measurable metastatic lesion (within 6 to 12 weeks of entry; at least one lesion \> 2cm in the longest dimension)
Exclusion
- Less than 18 years of age
- Pregnant or breastfeeding
- Inadequate venous access (defined as contralateral antecubital or equivalent venous access sites which are required for study drug injection and PK blood sampling, respectively)
- Uncontrolled glaucoma or retinopathy (e.g. macular degeneration) treated in the past year
- Cataracts or other lens opacities
- Any ophthalmologic intervention within the last 30 days (e.g., cataract extraction, laser procedure or equivalent, anti-VEGF treatment for macular degeneration. Topical treatments including antibiotics for conjunctivitis are allowed.)
- Patient received external beam therapy or chemotherapy within the last 30 days
- Any history of head and neck radiotherapy
- Karnofsky performance status is less than 60 (ECOG status \> 2)
- Serum creatinine is greater or equal to 2.0 mg/dL
- Total bilirubin greater or equal to 1.5 times upper limit of normal
- SGOT/AST or SGPT/ALT greater or equal to 3 times upper limit of normal (patients with metastatic liver disease are eligible if transaminase elevation is \> 5 times the upper limit of normal)
- Received an investigational compound and/or medical device within 30 days before admission into this study
- Administered a 99mTc-labeled radioisotope \< 3 days prior to imaging or \< 7days prior to imaging for other diagnostic radioisotopes with half lives greater than 24 hours
- Any known allergy or sensitivity to iodine. Iodinated X-ray contrast hypersensitivity is not an exclusion.
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-injection follow-up examinations
- Determined by the Investigator to be clinically unsuitable for the study
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00747825
Start Date
December 1 2009
End Date
September 1 2011
Last Update
October 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-4283